Review article: omega-3 fatty acids - a promising novel therapy for non-alcoholic fatty liver disease

The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association

“…Omega-3 fatty acids, currently approved in the United States to treat hypertriglyceridemia, have been investigated to treat NAFLD both in animal models and in humans ( 141 ). A recent review by Masterton et al ( 142 ), of published literature related to omega-3 fatty acids in NAFLD, found experimental evidence to support their use but RCT that randomized 247 non-diabetic patients with NASH to pioglitazone (30 mg / day), vitamin E (800 IU / day), or placebo for 24 months. Th e primary end point was an improvement in NAS ≥ 2 points with at least one-point improvement in hepatocellular ballooning and one-point improvement in either the lobular infl ammation or steatosis score, and no increase in the fi brosis score ( 122 ).…”

The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association

“…139 Omega-3 fatty acids, currently approved in the United States to treat hypertriglyceridemia, have been investigated to treat NAFLD both in animal models and in humans. 141 A recent review by Masterton et al, 142 of published literature related to omega-3 fatty acids in NAFLD, found experimental evidence to support their use but the interpretation of human studies was limited by small sample size and methodological flaws. A large multicenter study of one omega-3 fatty acid (eicosapentanoic acid) to treat NASH is ongoing in the United States.. More than a dozen other miscellaneous agents have been investigated in small, proof-of-concept studies and their detailed evaluation is beyond the scope of this guideline.…”

Omega-3 Fatty Acid Improve Non Alcoholic Fatty Liver Induced by High Fat Diet in Rats.

“…Component of metabolic syndrome include insulin resistance, dyslipidemia, type 2 diabetes, hypertension and hypertriglyceridemia [13,14]. When the liver gets fatty because of NAFLD, the ability of insulin to inhibit hepatic glucose production is impaired.…”